Literature DB >> 23424384

On specialty pharmaceuticals: reflections of a second-year medical student.

Ross E Breitbart1.   

Abstract

High cost and lack of evidence-based data for biologics used to treat rare diseases raise coverage questions for payers. Are clinical practice guidelines the answer?

Year:  2006        PMID： 23424384      PMCID： PMC3571059     

Source DB:  PubMed          Journal:  Biotechnol Healthc        ISSN： 1554-169X


  14 in total

Review 1.  Why don't physicians follow clinical practice guidelines? A framework for improvement.

Authors:  M D Cabana; C S Rand; N R Powe; A W Wu; M H Wilson; P A Abboud; H R Rubin
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

2.  The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease.

Authors:  J Charrow; H C Andersson; P Kaplan; E H Kolodny; P Mistry; G Pastores; B E Rosenbloom; C R Scott; R S Wappner; N J Weinreb; A Zimran
Journal:  Arch Intern Med       Date:  2000-10-09

Review 3.  Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations.

Authors:  Joel Charrow; Hans C Andersson; Paige Kaplan; Edwin H Kolodny; Pramod Mistry; Gregory Pastores; Ainu Prakash-Cheng; Barry E Rosenbloom; C Ronald Scott; Rebecca S Wappner; Neal J Weinreb
Journal:  J Pediatr       Date:  2004-01       Impact factor: 4.406

4.  A conversation with Jayson Slotnik, MPH, JD. Trying to make biotech attractive to payers.

Authors:  Jayson Slotnik
Journal:  Manag Care       Date:  2005-11

5.  Variability and growth in spending for outpatient specialty pharmaceuticals.

Authors:  C Daniel Mullins; Andrea R DeVries; Van Doren Hsu; Fanlun Meng; Francis B Palumbo
Journal:  Health Aff (Millwood)       Date:  2005 Jul-Aug       Impact factor: 6.301

6.  Uncertain miracle: a biotech drug extends a life, but at what price? For Ms. Lees, treatment bill now totals $7 million; her bones keep crumbling; guilt of another $1,400 day.

Authors: 
Journal:  Wall St J (East Ed)       Date:  2005-11-16

7.  Lucrative niches: how drugs for rare diseases became lifeline for companies.

Authors:  Geeta Anand
Journal:  Wall St J (East Ed)       Date:  2005-11-15

8.  Making the case to managed care: the science of marketing biologics.

Authors:  Chuck Appleby
Journal:  Biotechnol Healthc       Date:  2004-12

Review 9.  The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

Authors:  E Loveman; C Green; J Kirby; A Takeda; J Picot; E Payne; A Clegg
Journal:  Health Technol Assess       Date:  2006-01       Impact factor: 4.014

10.  Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.

Authors:  Neal J Weinreb; Joel Charrow; Hans C Andersson; Paige Kaplan; Edwin H Kolodny; Pramod Mistry; Gregory Pastores; Barry E Rosenbloom; C Ronald Scott; Rebecca S Wappner; Ari Zimran
Journal:  Am J Med       Date:  2002-08-01       Impact factor: 4.965
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.